Nichole Tucker

FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.

The FDA has okayed PD-1 inhibitor for the treatment of adults with advanced Merkel cell carcinoma.

In the largest study of CAR T-cell therapy, ZUMA-7, a key secondary end point was met with axicabtagene ciloleucel treatment in patients with relapsed or refractory large B-cell lymphoma.

In an interview, Randall Oyer, MD, explained the need to improve the impact of treatment-related adverse reactions using a multidisciplinary approach to enhance the lives of cancer survivors.

Anti-VISTA therapy may be the therapy type to be used with PD-1/PD-L1 inhibitors to treat patients with advanced solid tumors, expert say. One agent, KVA12123, has just entered phase 1 clinical research.

In an interview with Targeted Oncology, Christopher Chambers, MD, discussed how primary care physicians are involved with the diagnosis of cancer and the challenges faced with early detection.

In an interview with Targeted Oncology, Matthew Manning, MD, FASTRO, discussed the many radiation oncology tasks that have been improved with AI and its prospective utility in cancer diagnosis and treatment decisions.

The phase 3 EMBARK trial of enzalutamide plus leuprolide is the first to elicit a statistically significant improvement in metastasis-free survival in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.

Ripretinib now has 2 breakthrough therapy designations from the FDA and has been added to the NCCN guidelines for gastrointestinal stromal tumor.

Vorasidenib may break a 20-year gap in treatment advances for IDH-mutant low-grade glioma, according to phase 3 findings from the INDIGO study.

A phase 1 study is investigating anti-TIGIT therapy combined with immune checkpoint inhibition for the patients with metastatic microsatellite stable colorectal cancer.

A DESTINY-PanTumor02 trial update reveals the anti-tumor efficacy of trastuzumab deruxtecan in patients with HER2-expressing, advanced solid tumors.

The VENTANA PD-L1 Assay can now be used to detect PD-L1 expression in patients with non–small cell lung cancer to determine eligibility for treatment with cemiplimab.

With a broadened FDA label for abemaciclib, patients high-risk breast cancer can now be categorized based only on nodal status, tumor size, and tumor grade.

In an interview with Targeted Oncology, Brian A. Jonas, MD took a close look at the precision medicine landscape for AML and discussed key biomarkers and research needs for the future.

Findings from the phase 3 CONTACT-03 fail to add evidence supporting immune checkpoint inhibitor and tyrosine kinase inhibitor combination therapy for advanced renal cell carcinoma.

The FDA has planned a regular review of the biologic license application for cosibelimab for the treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.

YB-200, an investigational CEACAM antibody, has caught the attend of the FDA.

With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

The developer of avapritinib has announced full registrationL results from the phase 2 PIONEER study of avapritinib for the treatment of indolent systemic mastocytosis.

Treatment with (Z)-endoxifen in combination with exemestane plus goserelin in the phase 2 EVANGELINE is now underway.

A read out from the phase 3 KEYNOTE-859 at the February ESMO Virtual Plenary hints pembrolizumab/chemotherapy is a new treatment choice for locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Research shows a high occurrence of ibrutinib-related cardiotoxicity in patients with cancer. This is the first study showing such evidence.

In the phase 3 TORCHLIGHT study, survival advantages were shown with the combination of toripalimab and the chemotherapy agent nab-paclitaxel in patients with recurrent/metastatic triple-negative breast cancer treated in Chinese centers.

Further guidance from the FDA will be requested for the new drug application submission for SGX301 for the treatment of early-stage cutaneous T-cell lymphoma.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Patients with acute myeloid leukemia given annamycin demonstrated tolerable safety and preliminary efficacy with the agent, according to topline results from a phase 1/2 study.